Anaemia in chronic kidney disease – a review

Show simple item record Kok, Elandre 2021-11-18T07:13:35Z 2021-11-18T07:13:35Z 2020
dc.description.abstract The management of anaemia in chronic kidney disease (CKD) patients is a complex, multifaceted process reliant on the administration of exogenous erythropoiesis stimulating agents (ESAs) and iron supplements to ensure the adequate production of viable erythrocytes. Recommended best practice guidelines should be adhered to in order to ensure favourable treatment outcomes whilst minimising the risks often associated with ESA therapy. A paucity in readily available, accurate data makes quantifying the extent to which renal anaemia affects our population and how it is managed challenging, however it is expected to follow international trends. Novel preparations for treating renal anaemia are currently in the clinical trial phase, therefore the potential benefits and risks have yet to be confirmed. en_ZA
dc.description.department Pharmacology en_ZA
dc.description.librarian pm2021 en_ZA
dc.description.uri en_ZA
dc.identifier.citation Kok, E. 2020, 'Anaemia in chronic kidney disease – a review ', South African General Practitioner, vol. 1, no. 5, pp. 189-190. en_ZA
dc.identifier.issn 2706-9613 (print)
dc.identifier.issn 2706-9621 (online)
dc.identifier.other 10.36303/SAGP.2020.1.5.0051
dc.language.iso en en_ZA
dc.publisher Medpharm Publications en_ZA
dc.rights © 2020 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons License. en_ZA
dc.subject Anaemia en_ZA
dc.subject Patient en_ZA
dc.subject Chronic kidney disease (CKD) en_ZA
dc.subject Erythropoiesis stimulating agent (ESA) en_ZA
dc.title Anaemia in chronic kidney disease – a review en_ZA
dc.type Article en_ZA

Files in this item

This item appears in the following Collection(s)

Show simple item record